Kaminsky, Z
Wilcox, H C
Eaton, W W
Van Eck, K
Kilaru, V
Jovanovic, T
Klengel, T
Bradley, B
Binder, E B
Ressler, K J
Smith, A K
Article History
Received: 5 June 2015
Accepted: 14 June 2015
First Online: 25 August 2015
Competing interests
: ZK is an inventor on patent applications for DNA methylation biomarker-based prediction of PPD, suicide and PTSD. ZK received consultant fees from Janssen Research and Development, LLC. BB receives grant support or has received awards from AFSP and the American Psychoanalytic Association Psychoanalytic Research Fund. KJR has received funding from the Burroughs Wellcome Fund, NIH, and he has an unrelated role as the cofounder of Extinction Pharmaceuticals for development of <i>N</i>-methyl-D-aspartate-based therapeutics. EBB receives grant support from the 7th framework program of the European Community (ERC starting grant, the German Federal Ministry of Education and Research, ERANet-Neuron and NIH. EBB is inventor on patent applications related to using <i>FKBP5</i> and <i>ABCB1</i> genotypes in the prediction of antidepressant response and genetic predictors of treatment emergent suicidal ideation. AKS receives or has received research support from the American Foundation for Suicide Prevention, Schering Plough Pharmaceuticals, NARSAD, the Conquer Cancer Foundation and NIH. The remaining authors declare no conflict of interest.